Devlies Pharma SRL
0.8 FTEThe score of Devlies Pharma shows with a free account.
See the score- Summary? / 5
- Solvency
- Liquidity
- Interest coverage
- Profitability
- Leverage
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -5 % Total assets -13 % Headcount (avg FTE) 0 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Devlies Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −13,894 € | ||||
| Equity | 149,856 € | ||||
| Cash | 26,833 € | ||||
| EBITDA | 62,906 € | ||||
| Total assets | 675,641 € |
Filed annual accounts
- Year ended 30 Jun 2025filed on 15 Dec 2025
- Year ended 30 Jun 2024filed on 30 Dec 2024
- Year ended 30 Jun 2023filed on 18 Dec 2023
- Year ended 30 Jun 2022filed on 30 Dec 2022
- Year ended 30 Jun 2021filed on 21 Dec 2021
Devlies Pharma's financial analysis
- Solvency22.2%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Devlies Pharma
Devlies Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0877.804.765
- VAT number
- BE0877804765
- Peppol
- Registered · 0208:0877804765 · as of 25 Oct 2026
- Legal form
- SRL
- Incorporated
- 09 Dec 2005
- Registered office
- 8511 Kortrijk
- Size
- Micro · 0.8 FTE
- Latest accounts
- 2025 · filed on 15 Dec 2025
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Devlies Pharma (SRL) has been based in Kortrijk since 2005, active in: retail sale of pharmaceutical products. For 2025, it reports a net loss of 13,894 € and equity of 149,856 €; its revenue is not published. With 0.8 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 22.2%, below the median of its sector (44.2%).
Companies similar to Devlies Pharma
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie Louchez-Bouckaert Retail sale of pharmaceutical products Courcelles · balance sheet 894,008 €
- Apotheek De Ridder-Cloet Retail sale of pharmaceutical products Sint-Gillis-Waas · balance sheet €1.31m
- ViOph.arma Retail sale of pharmaceutical products Frameries · balance sheet 689,435 €
- Kapelfarma Retail sale of pharmaceutical products Kontich · balance sheet 653,987 €
- Geassocieerde Apotheek Merksem Retail sale of pharmaceutical products Antwerp · balance sheet 623,918 €
- Smith Pharma Retail sale of pharmaceutical products Willebroek · balance sheet 610,521 €
- LS Pharma Retail sale of pharmaceutical products Gembloux · balance sheet 749,318 €
- Vermunicht Retail sale of pharmaceutical products Hulshout · balance sheet 602,591 €
Frequently asked questions about Devlies Pharma
What is the revenue of Devlies Pharma?
Devlies Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Devlies Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0877804765 for Devlies Pharma, if the company is VAT-registered. Its company number (CBE) is 0877.804.765.
Where is the registered office of Devlies Pharma?
According to the CBE register, the registered office of Devlies Pharma is in 8511 Kortrijk.
What is the equity of Devlies Pharma?
At the close of the 2025 financial year, the equity of Devlies Pharma amounts to 149,856 €, a solvency of 22.2% of total assets.
How many people work at Devlies Pharma?
0.8 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Devlies Pharma?
The register lists 4 active mandates at Devlies Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Devlies Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →